CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
Biomarkers
A001 Monitoring response to immunotherapy in melanoma by quantification of circulating tumor
DNA with droplet digital PCR. Simon Chang-Hao Tsao, Jonathan Weiss, Christopher Hudson, Andreas
Behren, Witkowski Tom, Christopher Christophi, Alexander Dobrovic, Jonathan Cebon.
A002 Serum biomarkers of VEGF-A and TGF-β1 predict pathological response and survival of
esophageal cancer patients treated with neoadjuvant chemoradiotherapy and esophagectomy. Jason
Chia-Hsien Cheng, Yun Chiang, Feng-Ming Hsu, Chiao-Ling Tsai, Chih-Hung Hsu, Jang-Ming Lee.
A003 Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemoimmunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway
sustained by ICOS. Ornella Franzese , Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, Mariangela
Panetta, Maria Laura Foddai , Angela Santoni, Paola Nisticò.
A004 Upregulation of soluble programmed death ligands in patients with colorectal cancer. Jipei
Du, Yao Cheng, Zhigang Mao, Shiping Liao, Yanjiang Zheng, Ji Zhang, Yufang Wang.
A005 Flow cytometric profiling the human tumor microenvironment of biopsies and surgical
resections to guide clinical development of immunotherapeutics. Mark A Bittinger, Robert E Jones, Mark
M Awad, Meghana M Kulkarni, Shohei Koyama, Hajime Asahina, Grit S Herter-Sprie, Christina G Almonte,
Abigail A. Santos, Jessie M. English, Julianne Barlow, William G. Richards, Peter S. Hammerman, Scott J
Rodig, Raphael Bueno, Kwok-Kin Wong.
A006 Analysis of immune checkpoint control protein co-expression in breast and ovarian cancer
using novel rabbit monoclonal antibodies and multiplex IHC. Matthew R Silver, Jennifer E Ziello, Herbert
Haack.
A007 Bim as a predictive T cell biomarker for response to anti-PD-1 therapy in metastatic melanoma
(MM). Roxana S Dronca, Svetomir N Markovic, Lisa A Kottschade, Wendy Nevala, Haidong Dong.
A008 Discriminant function for predicting survival of lung adenocarcinoma patients developed by
using immune parameters of PD-L1, Gal-9 and XAGE1 expression on tumor cells and T cell infiltration
score. Yoshihiro Ohue, Kurose Koji, Mikio OKa, Eiichi Nakayama.
A009 IgG4: A new tool to predict the risk of disease progression in melanoma. Panagiotis
Karagiannis, Federica Villanova, Debra H Josephs, Isabel Correa, Mieke Van Hemelrijck, Carl Hobbs, Louise
Saul, Isioma U Egbuniwe, Isabella Tosi, Kristina M Ilieva, Emma Kent, Eduardo Calonje, Mark Harries, Ian
Fentiman, Joyce Taylor-Papadimitriou, Joy Burchel, James F Spicer, Katie E Lacy, Frank O Nestle, Sophia N
Karagiannis.
A010 Cancer immunotherapy biomarker profiling assay. Alex Chenchik, Leonid Iakoubov, Michael
Makhanov, Costa Frangou.
A011 Gene expression signatures of effector immune cell abundance are significantly associated with
recurrence risk in colon cancer. Angela Tatiana Alistar, Julia Chifman, Ralph D'Agostino, Lance D. Miller.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A012 A novel biomarker CRG1 in cetuximab resistant colorectal cancer. Ih-Yeon Hwang, Dae-Hee Lee,
Dong-Hoon Jin, Tae-Won Kim.
A013 Biomarker development for cancer immuno-oncology/immuno-therapy: Simultaneous digital
counting of nucleic-acids and proteins at 800-plex. Joseph Beechem.
A014 Endogenous anti-β-glucan antibodies and FcgRIIA (CD32a) single nucleotide polymorphisms
(SNP) as potential predictive biomarkers for the efficacy of Imprime PGG immunotherapy in cancer
patients. Nandita Bose, Anissa Chan, Adria Jonas, Nadine Ottoson, Xiaohong Qiu, Lindsay Wurst, Steven
Leonardo, Peter Maimonis, Katie Ertelt, Ben Harrison, Keith Gorden.
Tumor Microenvironment and Cross Talk with the Immune System
A015 Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor
cells by monocyte-derived macrophages. Nandita Bose, Adria Jonas, Xiaohong Qiu, Anissa SH Chan,
Nadine R Ottoson, Jeremy R Graff.
Biomarkers
A016 T cell landscape within primary melanoma as a predictive biomarker of survival after cancer
vaccination in patients with metastatic disease. Angela Vasaturo, Altuna Halilovic, Kalijn Bol, Dagmar
Verweij, Patricia Groenen, Han van Krieken, Willeke Blokx, Jolanda de Vries, Johannes Textor, Carl G Figdor.
A017 PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell
lung cancer (NSCLC). Marcin Kowanetz, Hartmut Koeppen, Wei Zou, Sanjeev Mariathasan, Matthew
Hellmann, Mark Kockx, Colombe Chappey, Edward Kadel, Dustin Smith, Natasha Miley, Vincent Leveque,
Roel Funke, Alan Sandler, Ian McCaffery, Lukas Amler, Daniel Chen, Priti Hegde.
A018 Onset of dysthyroidism during treatment with immune checkpoint inhibitors is increased in
responder patients. Diego Signorelli , Michele Del Vecchio, Marina Garassino, Alice Intini, Maria Silvia Cona,
Michele Magni, Ettore Seregni, Massimo Di Nicola, Filippo De Braud.
A019 Prognostic significance of natural killer ligand expression in acute myeloid leukemia. Rachel
Koldej, Jane Ripley, Christopher Chan, Mark Smyth, Paul Neeson, David Ritchie, Travis Perera.
A020 The analyses of immune infiltrate and gene expression of MAGE antigens in bladder cancer
allow to explain and predict recurrence. Daniela Fenoglio, Paolo Traverso, Alessia Parodi, Francesca Kalli,
Giuseppina Conteduca, Samuele Tardito, Monica Curto, Francesca Ferrera, Federica Grillo, Luca Mastracci,
Francesco Minaglia, Alchiede Simonato, Giorgio Carmignani, Gilberto Filaci.
A021 Driver-Map ImmuneNet: A gene expression profiling panel for enumeration of immune and
stromal cell admixtures from tissue. Alex Chenchik, Gus Frangou, Leonid Iakoubov.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A022 RNA epigenetics: A new approach to understanding leukemia/lymphoma. Shengdong Ke,
James E Darnell, Robert B Darnell.
A023 The clinical utility of the modified Glasgow Prognostic Score in patients undergoing
potentially curative colorectal cancer resection. James H Park, Campbell SD Roxburgh, Paul G Horgan,
Donald C McMillan.
A024 Protein microarrays for the immunological profiling of melanoma. Jessica Duarte, Janique
Peyper, Katherine Woods, Simon Tsao, Georgina Long, Jonathan Cebon, Jonathan Blackburn.
A025 KRAS mutation and IL-22 receptor expression synergistically predict poor prognosis in
colorectal cancer. Nathan West, Sarah McCuaig, David Barras, Mauro Delorenzi, Sabine Tejpar, Tim
Maughan, Fiona Powrie.
A026 Validation of an assay to identify regulatory T cells by flow cytometry in global clinical trials.
Li Zhou, Krista D. Buono, Christina D. Swenson, Michelle Brien, Thomas W. Mc Closkey.
Clinical Trials of Cancer Immunotherapies
A027 A Phase I open-label, non-randomized study of recombinant compound interferon (rSIFN-co)
in patients with advanced solid tumors. Su Pin Choo, Wai Meng Tai, Maria Macapagal, Aziah Ahmad, Greg
Li, Mui Leng Goh, Matthew Ng, Tira Tan, Shao Weng Tan, Wan Teck Lim.
A028 PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a phase 1 study.
Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick Alexander Ott, Deborah
Jean Lee Wong, Gerrald Stteven Falchook, Manish R. Patel, Shubham Pant, Melinda Whiteside, Johanna C.
Bendell, Todd Michael Bauer, Filip Janku, Milind M. Javle, David S. Hong, Martin Oft.
A029 Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local
advance prostate cancer patients. Fernando T Kreutz.
A030 Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE
301 trial. Peter Ordentlich, Min-Jung Lee, Yusuke Tomita, Sunmin Lee, Saori Tomita, Scott Cruickshank,
Saranya Chumsri, Jane B. Trepel.
A031 CD8+T cells fail to form an effector memory in glioblastoma patients treated with dendritic cell
immunotherapy in combination with chemotherapy. Serena Pellegatta, Marica Eoli, Elena Anghileri, Sara
Pessina, Carlo Antozzi , Simona Frigerio, Gabriele Cantini, Maria Grazia Bruzzone, Bianca Pollo, Eugenio A.
Parati, Gaetano Finocchiaro.
A032 Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk
relapsed/refractory neuroblastoma patients. Holger N. Lode, Dominique Valteau-Couanet, Alberto
Garaventa, Juliet Gray, Victoria Castel, Isaac Yaniv, Nikolai Siebert, Christian Jensen, Stefanie Endres, Lena
Pill, Christin Eger, Diana Seidel, Madlen Jüttner, Silke Kietz, Karoline Ehlert, Evelyne Janzek, Carla Manzitti,
Ina Müller, Hans Loibner, Ruth Ladenstein.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A033 Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody,
KW-0761, in cancer patients. Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Toshihiko Doi, Hiroyoshi
Nishikawa, Mikio Oka, Ryuzo Ueda.
A034 Immune responses against tumor associated antigens are induced by treatment with the cellbased tumor vaccine MGN1601 in patients with renal cell carcinoma. Manuel Schmidt, Barbara Volz,
Kerstin Kapp, Viktor Gruenwald, Matthias Schroff, Burghardt Wittig.
A035 Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR-9 agonist MGN1703
– conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients.
Manuel Schmidt, Kerstin Kapp, Detlef Oswald, Matthias Schroff, Burghardt Wittig, Alfredo Zurlo.
A036 Anti-PD1 therapy and CD8 T cell invigoration in metastatic melanoma. Alexander Huang, Wei
Xu, Shannon Harmon, Felix Quagliarello, Ramin Herati, Kristen Pauken, Bertram Bengsch, Lynn Schuchter,
Ravi Amaravadi, Suzanne McGettigan, Tara Gangadhar, John Wherry.
A037 IMCgp100 ImmTAC: A new immunotherapeutic reagent for the treatment of malignant
melanoma. Johanne Pentier, Mary Connolly, Martina Canestraro, Ruth Ryan, Luise Weigand, Namir Hassan,
Annelise Vuidepot, Bent Jakobsen.
A038 The feasibility of inducing effective systemic immune responses to human metastatic
melanoma with intralesional secreted cytokines. Fred T. Valentine, Frederick M. Golomb, Matthew Haris,
Daniel F. Roses.
A039 Caspase-2 and oxidative-ER stress crosstalk regulates the exposure of “eat me” signal
calreticulin by high hydrostatic pressure treated cancer cells. Irena Kusova Moserova, Iva Truxova,
Abhishek G, Garg, Patrizia Agostinis, Piere Francois Cartron, Sarka Vosahlikova, Radek Spisek, Jitka
Fucikova.
A040 Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined
withchemotherapy in patients with metastatic, castration-resistant prostate cancer. Jitka Fucikova,
Michal Podrazil, Rudolf Horvath, Etienne Becht, Jirina Bartunkova, Radek Spisek.
A041 CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and
leukemia report from the Swedish phase I/IIa trial. Gunilla Enblad, Hannah Karlsson, Kristina I Wikstrom,
Magnus Essand, Barbara Savoldo, Malcolm K Brenner, Gianpietro Dotti, Martin Hoglund, Hans Hagberg,
Angelica Loskog.
A042 A predictive nomogram to determine CD137 upregulation on NK cells in patients receiving
monoclonal antibody therapy. Amani Makkouk, Cariad Chester, Serena Chang, Vandana Sundaram,
Manisha Desai, Inna Sayfer, Holden T Maecker, Holbrook E Kohrt.
A043 Safety and efficacy of a genetic vaccine targeting telomerase against various canine cancers.
Joseph A Impellizeri, Alessandra Gavazza, George Lubas, Eliana Greissworth, David Jemiolo, Gennaro
Ciliberto, Luigi Aurisicchio.
A044 Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles +
dendritic cells vaccine (TLPLDC) in patients with solid tumors. Julia M Greene, Diane F Hale, Erika J
Schneble, Xianzhong Yu, Pauline Nichol, Sook Yin, Thomas Wagner, George E Peoples.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A045 Dendritic cell vaccination with partial Treg depletion in relapsed glioblastoma – results from
the pilot phase of the HIT-HGG Rez Immunvac study. Matthias Eyrich, Jürgen Krauss, Mario Löhr, Antje
Technau, Johannes Rachor, Camelia Monoranu, Monika Warmuth-Metz, Matthias Wölfl, Christof Kramm, Paul
Gerhardt Schlegel.
A046 Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with
glioblastoma (GBM). David A Reardon, Jorg Dietrich, Thomas Kaley, Hui Gan, Gavin P Dunn, Timothy
Cloughesy, Michael Lim, Jennifer Clarke, Andrew Park, Linda Pan, Domenic W Lai, Joyson Karakunnel, Paul
Robbins, Rajesh Narwal, Ralph Venhaus.
A047 Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1
(PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Scott Antonia, Naiyer Rizvi, Julie
Brahmer, Sai-Hong Ou, Samir N Khleif, Wen-Jen Hwu, Martin Gutierrez, Patrick Schoffski, Omid Hamid, Jared
Weiss, Jose Lutzky, Michele Maio, John Nemunaitis, Dirk Jaeger, Ani Balmanoukian, Marlon C Rebelatto,
Keith E Steele, Xiaoping Jin, Paul B Robbins, John A Blake-Haskins, Neil H Segal.
A048 Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in
PSA defined biochemical recurrent prostate cancer patients. Jonathan F Head, Gregory A Daniels,
Michelle McKinney, Weg Ongkeko, Jessica Wang-Rodriguez, Kyoko Sakamoto, Robert L Elliott.
A049 Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12
in advanced breast cancer and melanoma patients. Francois Lebel, John A Barrett, Hongliang Cai, John
Miao, Suma Krishnan, Laurence JN Cooper.
A050 Local administration of CpG-B increases recurrence-free survival in early-stage melanoma
patients: Long-term follow-up of two randomized clinical trials evaluating adjuvant treatment. Tanja
D. de Gruijl, Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Barbara G. Molenkamp, Paul A.M.
van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh.
A051 Safety, feasibility and activity of intratumoral injection of activated autologous dendritic cells
in solid tumors: A phase I clinical trial. Vivek Subbiah, Ravi Murthy, David S Hong, Robert Prins, Chitra
Hosing, Robert Brown, Mary McGuire, Aung Naing, Siquing Fu, Quan Lin, Anthony P Conley, Indreshpal Kaur,
Marnix L Bosch.
A052 A clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected
melanoma patients; a vaccine to prevent recurrence. Lindy G Durrant, Poulam Patel, Christian
Ottensmeier, Clive Mulatero, Paul Lorigan, Rachael Metheringham, Victoria Brentville, Ian Daniels, Drew
Hannaman.
Drug Development
A053 Therapy with a non-blocking monoclonal antibody targeting soluble NKG2D ligand MIC
revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and
metastatic tumors. Jennifer Wu.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
Immune Regulation of T Cell Responses/Evolving Concepts in Cancer Immunology
A054 In vivo characterization of Ipilimumab T cell modulation and anti-tumor activity in a tumor
bearing humanized NSG mouse model. Meixia Bi, Chris Hopson, Tianqian Zhang, James smothers, Axel
Hoos.
A055 Potent therapeutic and immunological effects of the first T-BiTE derived from a TCR-mimic
antibody targeting intracellular oncoprotein WT1. Tao Dao, Dmitry Pankov, Andrew Scott, Tatyana
Korontsvit, Victoriya Zakhaleva, Manuel Direito de Morais Guerrerio, Yiyang Xu, Jingyi Xiang, Su Yan,
Nicholas Veomett, Nicholas Veomett, Leonid Dubrovsky, Michael Curcio, Ekaterina Doubrovina, Cheng Liu,
Richard J. O’Reilly, Richard J. O’Reilly, David A. Scheinberg, David A. Scheinberg, David A. Scheinberg.
A056 Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in
mice and patients. Christina Twyman-Saint Victor, Andrew Rech, Amit Maity, Ramesh Rengan, Kristen
Pauken, Kristen Pauken, Erietta Stelekati, Joseph Benci, Bihui Xu, Hannah Dada, Pamela Odorizzi, Ramin
Herati, Kathleen Mansfield, Dana Patsch, Ravi Amaravadi, Lynn Schuchter, Hemant Ishwaran, Rosemarie
Mick, Daniel Pryma, Xiaowei Xu, Michael Feldman, Tara Gangadhar, Stephen Hahn, E. John Wherry, Robert
Vonderheide, Andy Minn.
A057 Uni-CIDeCAR-T cells: MyD88/CD40-enhanced, Ab-directed CAR incorporating the CaspaCIDe®
safety switch. MyLinh T Duong, Matthew R Collinson-Pautz, Aaron E Foster, J Henri Bayle, David M
Spencer.
A058 GITRL-Fc, an immunotherapeutic agent that stimulates T-cell-mediated antitumor immune
response. Fumiko Axelrod, Hyun-Bae Jie, Erin Mayes, Jorge Monteon, Minu Srivastava, Rui Yun, Inkyung
Angie Park, Austin Gurney.
A059 Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a
rationale for clinical development as cancer immunotherapeutics. Kutlu Elpek, Christopher Harvey, Ellen
Duong, Tyler Simpson, Jenny Shu, Lindsey Shallberg, Matt Wallace, Sriram Sathy, Robert Mabry, Jennifer
Michaelson, Michael Briskin.
A060 Immunoproteasome deficiency is a feature of NSCLC with a mesenchymal phenotype and is
associated with restricted antigen presentation and poor outcome in patients. Satyendra C Tripathi,
Haley L Peters, Edwin J Ostrin, Ayumu Taguchi, Hiroyuki Katayama, Hong Wang, Amin Momin, Mohit K Jolly,
Muge Celiktas, Jaime Rodriguez, Carmen Behrens, Ignacio I Wistuba, Eshel Ben Jacob, Herbert Levine,
Jeffrey J Molldrem, Samir M Hanash.
A061 Tumor cell expression of PD-L1 is important in determining the in vivo fate of edited MCA
sarcomas. Takuro Noguchi, Jeffrey P Ward, Matthew M Gubin, Cora Arthur, Robert D Schreiber.
A062 Anti-LAP antibody promotes a tumor-specific immune response by targeting regulatory T
cells and TGF-β. Galina Gabriely, Andre da Cunha, Brendan Kenyon, Rafael Rezende, Murugaiyan Gopal,
Tyler Vandeventer, Howard L Weiner.
A063 Cancer cell expression of CCR2 regulates the PD-L1/ PD-1 immune checkpoint in breast cancer.
Miriam R Fein, Ana S. Almeida, Anaïs Eberhardt, Mikala Egeblad.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A064 Modeling checkpoint blockade inhibitor resistant immunoregulation induced by squamous
epithelial cancers. Stephen Mattarollo, Graham Leggatt, James Wells, Paul Lambert, Ian H Frazer.
A065 Genome-wide analysis of the cytosolic DNA sensing pathway. Chan-Wang J. Lio, Jenny Huang,
Anjana Rao* equal contribution, Sonia Sharma* equal contribution.
A066 Histone deacetylase 11 is an epigenetic regulator of T-cell pro-inflammatory function and
novel target for enhancing T-cell antitumor activity. David M Woods, Andressa L Sodre, Karrune Woan,
Alejandro Villagra, Amod Sarnaik, Jeffrey Weber, Eduardo M Sotomayor.
A067 Quality of initial activation of CD8 T cells specific for TRP1 determines long-term anti-tumor
immunity. Paul Tyler, Mariah Servos, Stephanie K Dougan.
A068 Imbalance in regulatory T (Treg) cells frequency in peripheral circulation of patients with oral
squamous cell carcinoma and their effects on growth of oral cancer. Sadhna Aggarwal, Satya N Das,
Suresh C Sharma.
A069 T-cell motility is controlled by homotypic interactions and serves as a biomarker for antitumor polyfunctionality. Navin Varadarajan, Ivan Liadi, Gabrielle Romain, Harjeet Singh, Laurence Cooper,
Badrinath Roysam.
A070 Genetic knockdown screens across tumor types unravel a diverse tumor immune-modulatome
landscape. Nisit Khandelwal, Tillmann Michels, Marco Breinig, Antonio Sorrentino, Isabel Poschke, Rienk
Offringa, Michal Lotem, Michael Boutros, Philipp Beckhove.
A071 Immune monitoring of ipilimumab treated patients reveals enhanced CD4+ T cell activation
correlated with diminished MDSCs. Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy
Gentilcore, Isabel Poschke, Giuseppe V Masucci, Johan Hansson , Rolf Kiessling.
A072 Reprogramming immune response with capsid-optimized AAV vectors for immunotherapy of
cancer. Munjal Pandy, Kellee Britt, George Aslanidi.
A073 Carrier-free delivery of cytokine to specifically expand adoptively transferred T cells for
enhanced cancer immunotherapy. Li Tang, Yiran Zheng, Llian Mabardi, Darrell J Irvine.
A074 Selective inhibition of HDAC6 augments T-cell central memory and enhances antitumor
functions: Implications in TIL therapy. Andressa Sodre Laino, David M Woods, Amod Sarnaik, Jeffrey
Weber, Eduardo M Sotomayor.
A075 Immunotherapy of malignant pleural mesothelioma using cMET specific T-cells. Thivyan
Thayaparan, Sjoukje J.C. van der Stegen, Ana C Parente Pereira Puri, Roseanna Maria Petrovic, James Spicer,
John Maher.
A076 CD40 stimulation overrides role of innate immune sensors for priming of T cells in cancer.
Katelyn T Byrne, Robert H Vonderheide.
A077 Unraveling predicted immunomodulatory effects of novel cancer-associated noncoding RNAs.
Antoine Tanne, Luciana Muniz, David Ting, Arnold Levine, Nina Bhardwaj, Benjamin Greenbaum.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A078 Computational discovery and experimental validation of novel drug targets in immunooncology. Arthur Machlenkin, Ofer Levy, Galit Rotman.
A079 Inhibition of HSP90 improves response to α-CTLA4 immunotherapy in melanoma. Rina M
Mbofung, Shruti Malu, Jodi A McKenzie, Rodabe N Amaria, Patrick Hwu.
A080 Targeted genome modifications for improved adoptive immunotherapy. Julien Valton, AnneSophie Gautron, Alexandre Juillerat, Philippe Duchateau, Laurent Poirot.
A081 A PD-L1-targeted Probody provides antitumor efficacy while minimizing induction of systemic
autoimmunity. Chihunt Wong, Li Mei, Kenneth R Wong, Elizabeth E.M. Menendez, Olga Vasiljeva, Jennifer H
Richardson, James W West, Michael Kavanaugh, Bryan A Irving.
A082 Developing a PD-1 based inhibitory chimeric antigen receptor (ICAR) for co-expression, to
overcome off-tumor toxicity when targeting ErbB2 using engineered T cells. Roseanna Maria Petrovic,
Scott Wilkie, John Maher.
A083 Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinoma.
Deborah Ayeni, Ping-Chih Ho, Curtis Perry, Susan Kaech, Katerina Politi.
A084 Identification of mutation-reactive T cells in patients with gastrointestinal cancers. Mélissa
Mathieu, Sandy Pelletier, David Laperrière, Sylvie Mader, Simon Turcotte.
A085 Orchestration and prognostic significance of immune checkpoints in the microenvironment of
primary clear cell renal cell cancer. Nicolas A Giraldo, Becht Etienne, Laetitia Lacroix, Yann Vano, Rafael
Sanchez-Salas, Pierre Validire, Virginie Verkarre, Arnaud Mejean, Marie-Caroline Dieu-Nosjean, Stephane
Oudard, Xavier Cathelineau, Wolf H Fridman, Catherine Sautès-Fridman.
A086 Real-time in vivo characterization of spatiotemporal immunotherapeutic response to high
intensity focused ultrasound with a novel NF-kB reporter model of human breast cancer. Mary D
Dockery, Megan E Poorman, Vandiver L Chaplin, Ryan A Spears, Charles F Caskey, William A Grissom, Todd
D Giorgio.
A087 Phase separation of signaling molecules promotes T cell receptor signal transduction. Xiaolei
Su, Jon Ditlev, Enfu Hui, Sudeep Banjade, Julia Okrut, Jack Taunton, Mike Rosen, Ron Vale.
A088 Increase lymphocyte infiltration overcomes tumor resistance to checkpoint blockade. Haidong
Tang, Yang Wang, Yang-Xin Fu.
A089 The circulating memory B cell compartment of breast cancer patients is depleted in
comparison with healthy volunteers. Matthew W Fittall, Dina Levi, Angela Clifford, Vandna Shah, Anthony
Cheung, Andrew Tutt, Sophia N Karagiannis.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
Tumor Antigens for Targeting: Insight from Genomics
A090 Exploring folate receptor α immunotherapy of breast carcinomas: Human monocytic cellmediated killing triggered by IgG1 and IgE antibodies. Matthew W Fittall, Anthony Cheung, Gyula M
Petranyi, Diana Rodriguez-Dominguez, Heather J Bax, Panagiotis Karagiannis, Kristina M Ilieva, Andrew Tutt,
Sophia N Karagiannis.
Immune Regulation of T Cell Responses/Evolving Concepts in Cancer Immunology
A091 Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity
leading to durable, complete responses, as monotherapy and in combination with checkpoint
inhibition. David Schaer, Yanxia Li, Stephen Castaneda, Ivan Inigo, David Surguladze, Xiaohong Xu, Desiree
Nugent, Mary Murphy, Gerald Hall, Karim Benhadji, Susan Guba, Yiwen Li, Michael Kalos, Kyla Driscoll.
A092
Surpassing the emerging immune-checkpoint inhibitor market. Michael P Vitek.
A093 Interferon gamma and post-translational modifications control the dynamics and plasma
membrane association of IL15RA expressed by triple negative breast cancer (TNBC). Pierfrancesco
Marra, Sumi Mathew, Steven Catchpole, Alessandra Facchetti, Andrew Tutt.
A094 IL-2 complex rescues CD8+ T cell tolerance for cancer immunotherapy. Lauryn E Swier, Melissa
M Berrien-Elliott, Ryan M Teague.
A095 New genes for enhancing T cell function in adoptive cell therapy of cancer. Gideon Gross,
Aviad Pato, Hadas Weinstein-Marom, Noam Levin, Alon Margalit, Orit Itzhaki, Michal Besser, Tamar Peretz,
Arthur Machlenkin, Michal Lotem.
A096 CX3CR1 expression levels distinguish CD8+ memory T cells surveying non-lymphoid tissues
from effector memory and central memory T cells. Carmen Gerlach, E. Ashley Moseman, Scott M
Loughhead, David Alvarez, Anthonie J Zwijnenburg, Lisette Waanders, Ulrich H von Andrian.
A097 Potentiating adoptive T cell therapy through orthogonal cytokine-receptor engineering.
Jonathan T Sockolosky, Jamie Spangler, Melissa McCracken, Chris King, David Baker, K. Christopher Garcia.
Microbiome
A098
Helicobacter-specific T cell responses in gut homeostasis and disease. Mo Xu, Dan R. Littman.
A100 Cooperative defense against acute Clostridium difficile infection is mediated by two Innate
Lymphoid Cell subsets. Michael C Abt, Brittany B Lewis, Lilan Ling, Rebecca A Carter , Boj Susac, Eric G
Pamer.
A101 Antitumor efficacy of anti-CTLA4 antibody is dependant on gut microbiota. Marie Vetizou,
Jonathan Pitt, Romain Daillere, Laurence Zitvogel.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A102 The effect of defined skin resident commensals in skin immunity. Vanessa K Ridaura, Jan
Claesen, Michael A Fischbach, Yasmine Belkaid.
A103
Regulation of Toll-like receptor expression in intestinal epithelial cells. April Price, Greg Barton.
Preclinical Models
A104 Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells
and vaccination. Clare Y Slaney, Jennifer A Westwood, Paul A Beavis, Phillip K Darcy, Michael H Kershaw.
Tumor Microenvironment and Cross Talk with the Immune System
A105 Cross-talk between tumors can affect responses to therapy. Christel Devaud, Jennifer A
Westwood, Liza John, Carmen SM Yong, Paul A Beavis, Linda A Snyder, Reto A Schwendener, Darcy K
Phillip, Michael H Kershaw.
Tumor Antigens for Targeting: Insight from Genomics
A107 Ewing sarcoma preferentially express CD99 isoform variant 5 compared to normal tissues.
Sabine Heitzeneder, John F Shern, Javed Khan, Crystal L Mackall.
A108 Expitope: A webserver for epitope expression. Silke Raffegerst, Kerstin Haase, Maja Buerdek,
Christian Ellinger, Dmitrij Frishman, Dolores Schendel.
A109 Exploring neoantigens and immunological response in GBM patients after individualized
Prophage vaccination. John Castle, Dan Levey, Elise Drouin, Nicholas Wilson, Steven Schoenfeld, Orin
Bloch, Jennifer Buell.
A110 Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Mathias Vormehr,
Sebastian Kreiter, Niels van de Roemer, Mustafa Diken, Martin Löwer, Fulvia Vascotto, Jan Diekmann,
Sebastian Boegel, Barbara Schroers, Arbel D. Tadmor, Özlem Türeci, Ugur Sahin.
A111 The immunopeptidomic landscape of ovarian carcinoma. Heiko Schuster, Janet Peper, Kevin
Roehle, Hans-Georg Rammensee, Stefan Stevanovic, Philipp Wagner.
A112 Mapping the impact of proteasome inhibitor therapy on the antigenic landscape of multiple
myeloma: Identifying robust targets for T cell immunotherapy. Daniel J Kowalewski, Simon Walz, Linus
Backert, Heiko Schuster, Oliver Kohlbacher, Lothar Kanz, Helmut R Salih, Hans-Georg Rammensee, Stefan
Stevanovic, Juliane S Stickel.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A113 iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic
leukemia patients based on patient-individual tumor-specific variants. Armin Rabsteyn, Christina
Kyzirakos, Christopher Schröder, Marc Sturm, Christopher Mohr, Mathias Walzer, Ulrike Pflückhahn, Michael
Walter, Magdalena Feldhahn, Karoline Laske, Michael Bonin, Martin Ebinger, Stefan Stevanovic, Stefan
Stevanovic, Peter Bauer, Oliver Kohlbacher, Cecile Gouttefangeas, Cecile Gouttefangeas, Hans-Georg
Rammensee, Hans-Georg Rammensee, Rupert Handgretinger, Rupert Handgretinger, Peter Lang, Peter
Lang.
A114 Towards personalized cellular adoptive immunotherapy targeting tumor specific neoantigens in
microsatellite unstable colorectal cancers. Pauline Maby, Mohamad Hamieh, Hafid Kora, David Tougeron,
Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Tessa Fredriksen, Nicolas Elie, Emilie Fauquembergue,
Aurélie Drouet, Jérôme Leprince, Jacques Benichou, Jacques Mauillon, Florence Le Pessot, Richard Sesboüé,
Thierry Frébourg, Jérôme Galon, Jean-Baptiste Latouche.
A115 Cancer vaccine development for hepatocellular carcinoma – HEPAVAC. Luigi Buonaguro, Sarah
Kutscher, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Francesco Izzo, Alfred Koenigsrainer, Markus
Loeffler, Phillip Mueller, Andrea Mayer, Hans-Georg Rammensee, Bruno Sangro, Sven Francque, Danila
Valmori, Toni Weinschenk, Harpreet Singh-Jasuja.
A116 A predictive model to identify immunogenic neoepitopes in patients with melanoma treated
with CTLA-4 blockade. Diego Chowell, Sri Krishna, Alexandra Snyder, Makarov Vladimir, Timothy A. Chan,
Karen S. Anderson.
A117 Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3
K27M mutation. Yafei Hou, Gary Kohanbash, Kaori Okada, Shruti Shrivastav, Matthew Smith-Cohn,
Theodore Nicolaides, Sabine Mueller, Angel Montero Carcaboso, Ian F Pollack , Hideho Okada.
Tumor Microenvironment and Cross Talk with the Immune System
A118 Transforming growth factor-beta as a therapeutic target for pancreatic cancer. Ismail Meraz,
Leoncio Vergara, Sarah Suki, Prem Siddharth Gunamalai, Rita Elena Serda.
A119 Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates
immune-mediated tumor rejection. Elizabeth E Evans, Holm Bussler, Sebold Torno, Crystal Mallow, Laurie
A Winters, Christine Reilly, Ekaterina Klimatcheva, Janaki Veeraraghavan, Alan S Jonason, Maria Scrivens,
Renee Kirk, Alan Howell, Leslie Balch, John E Leonard, Mark Paris, Terrence L Fisher, Ernest S Smith, Maurice
Zauderer.
A120 Tumor educated B cells acquire LAP/TGF-β1 and PD-L1 expression and suppress antitumor
immune response. Yu Zhang, Richard Morgan, Chuan Chen, Yancheng Cai, Seung-Uon Shin, Hyun-Mi Cho,
Ahmed Al Bayati, Augustin Pimental, Joseph D Rosenblatt.
A121 Complement activation is critical for tumor progression in an orthotopic immunocompetent
model of lung cancer. Jeff Kwak, Howard Li, Jennifer Laskowski, Mary Weiser-Evans, Joshua Thurman,
Raphael A Nemenoff.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A122 Non-small cell lung cancer cells induce PD-L1 expression in the tumor microenvironment in an
orthotopic mouse model of lung cancer. Howard Li, Maria McSharry, Eric Clambey, Teresa Nguyen, Eoin
McNamee, Mary Weiser-Evans, Raphael Nemenoff.
A123 CD14+ monocyte recruitment, transformation and support of tumor survival in a lung cancer
model. Erin Schenk, Allan Dietz.
A124 Tertiary lymphoid structures: Predictors of effective anti-tumor immunity in human breast
cancer? Soizic Garaud, Laurence Buisseret, Chunyan Gu-Trantien, Gert Van den Eynden, Alexandre de
Wind, Edoardo Migliori, Roberto Salgado, Denis Larsimont, Martine Piccart, Karen Willard-Gallo.
A125 Breaking the tension: Investigating a link between tissue mechanics and tumor immunity in
breast cancer. Ori Maller, Luke Cassereau, Jason Northey, Brian Ruffell, Ryan Hill, Miranda L Broz, Jennifer
M Munson, Melody A Swartz, Kirk C Hansen, Matthew F Krummel, Lisa M Coussens, Valerie M Weaver.
A126
Taking out the trash: Efferocytosis in the tumor microenvironment. Rebecca S Cook.
A127 Innate crosstalk between ILC and interstitial macrophages promotes lung cancer regression in
response to IL-12 therapy. Jake Y Henry, Frederick Arce, Burkhard Becher, Karl S Peggs, Sergio A
Quezada.
A128 Suppression of anti-tumor immune responses in tumor-associated tertiary lymphoid structures
by regulatory T cells. Nikhil S Joshi, Tyler Jacks.
A129 Tumor-associated lymphatic vessels as a biomarker of antitumor immunity. Ryan Lane, Jamie
Booth, Christopher Loo, Amanda W Lund.
A130 Immune regulation of EMT and metastatic competence in breast tumor progression. Robiya
Joseph, Rama Soundararajan, Anurag Paranjape, Sendurai Mani.
A131 Measurement of immune infiltration in ER, PR, and HER2 IHC subtypes reveals populations that
may benefit from immunotherapy. Pinky Tripathi, Nam Tran, Raghavkrishna Padmanabhan, Richard
Hartsfield, Edward J Moler, Nicholas Hoe, Kenneth Bloom.
A132 Nonalcoholic fatty liver disease causes selective CD4+ lymphocytes loss and promotes
hepatocarcinogenesis. Chi Ma, Aparna Kesarwala, Daniel McVicar, Achim Weber, Mathias Heikenwaelder,
Tim Greten.
A133 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE
tissue sections. James R Mansfield, Clifford C Hoyt, Edward Stack, Michael Feldman, Carlo Bifulco, Bernard
Fox.
A134 The immunoregulatory enzyme IDO induces resistance to common chemotherapy drugs via
base excision repair pathway. Saman Maleki Vareki, Chen Di, Christine Di Cresce, Peter J Ferguson, Mark
Vincent, Weiping Min, Xiufen Zheng, James Koropatnick.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A135 Phosphodiesterase-5 inhibition augments postoperative natural killer cell antitumor immunity
by reducing myeloid-derived suppressor cell function. Lee-Hwa Tai, Almohanad A Alkayyal, Christiano
Tanese de Souza, Amanda Lynn Leslie, Shalini Sahi, Sean Bennett, Jiqing Zhang, John C Bell, Rebecca A
Auer.
A136 Myeloid cells regulate pancreatic carcinogenesis and remodeling. Yaqing Zhang, Wei Yan, Esha
Mathew, Kevin T Kane, Marina Pasca di Magliano.
A137 Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and PD-1
blockade provides effective tumor control through a mechanism of epitope spreading. Genevieve M
Weir, Olga Hrytsenko, Marianne Stanford, Mohan Karkada, Neil Berinstein, Marc Mansour.
A138 Identification of key immune regulators that control obesity-induced liver inflammation and
diseases. Zhenyu Zhong, Atsushi Umemura, Shuang Liang, Michael Karin.
A139 Adenosine regulates in situ tumor vaccination by radiation therapy. Erik Wennerberg, Noriko
Kawashima, Sandra Demaria.
A140 Viral-like nanoparticles for tumor immunotherapy by in situ vaccination mediate potent
antitumor immunity. Patrick Lizotte, Amy Wen, NIcole Steinmetz, Steven Fiering.
A141 The vigorous immune microenvironment of microsatellite instable colon cancer isbalanced by
multiple counter-inhibitory checkpoints. Nicolas J Llosa, Franck Housseau, Elizabeth Wick,
Hechenbleikner Lizzy, Michael Cruise, Robert Anders, Cynthia Sears, Drew M Pardoll, Hongni Fan, Nicholas
Siegel, Lee Blosser, Ada Tam, Hao Wang.
A142 An in vivo functional genomics screen identifies molecular determinants of adaptive immune
rejection. Casey W Shuptrine, Elana J Fertig, Marsha Salcie-Gautreaux, Louis M Weiner.
A143 Melanoma cell resistance to phagocytosis is unrelated to expression of conventional “eatme/don’t eat-me” signals. Katie L Anderson, Debra Lins, Jens-Peter Volkmer, Yoji Shimizu, Irving L
Weissman, Matthew Mescher, Jaime Modiano.
A144 Cooperative effects of TGFβ and activin A control regulatory T cell numbers in irradiated
tumors. Claire I Vanpouille-Box, Silvia Formenti, Sandra Demaria.
A145 Radiation therapy induces tumor-promoting immune suppression in the microenvironment of
pancreatic carcinoma. Lena Tomkötter, Gregor Werba, Susanna Nguy, Sara Alothman, Dalia Alqunaibit,
Shaun Tiwari, Nancy Ngoc Giao Ly, Donnele Daley, Atsuo Ochi, Rocky Barilla, Alejandro Torres-Hernandez,
Ilenia Pellicciotta, Kevin Du, George Miller.
A146 The role of SOCS-1 in stimulating melanoma development through tyrosine-kinase receptors
and MAPK pathways and prevents antitumour immunity by PD-L1 expression. Rodrigo Berzaghi, Vera
SC Maia, Felipe V Pereira, Filipe Manegatti De Melo, Luiz R. Travassos, Luiz R. Travassos.
A147 Sunitinib upregulates IFNγ-STAT1 signaling to modulate the tumor immune microenvironment
in renal cell carcinoma. Xian-De Liu, Anh Hoang, Mianen Sun, Zhou Lijun, Zhiyong Ding, Xuesong Zhang,
Shanshan Bai, Nizar Tannir, Eric Jonasch.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A148 Protecting CAR T cells from immunosuppressive cytokines present in the tumor
microenvironment. Sujita Sukumaran, Somala Mohammed, Norihiro Watanabe, Pradip Bajgain, Helen E
Heslop, Cliona M Rooney, Malcolm K Brenner, Ann M Leen, Juan F Vera.
A149 Evaluating immune contexture in syngeneic mouse models of cancer. Sapna Yadavilli,
Sabyasachi Bhattacharya, Ashleigh Hahn, Laura Seestaller-Wehr, David Kilian, Meixia Bi, Shu-Yun Zhang,
Nicholas Vitali, Michael Adam, Yufeng Li, Niranjan Yanamandra, Roopa Srinivasan, Axel Hoos.
A150 Tertiary lymphoid structures in non-small cell lung cancer and effects of chemotherapy. Karina
Silina, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Periklis Foukas, Aija Line, Maries
van den Broek.
A151 Radiation-induced TGFβ regulates the myeloid compartment to suppress antitumor immunity.
Alba Gonzalez Junca, Ilenia Pellicciotta, Kyla Driscoll Carroll, David Schaer, Mary Helen Barcellos-Hoff.
A152 The Macrophage Migration Inhibitory Factor promotes breast cancer metastasis through
interaction with the host immune response. Kristen N Balogh, Janet V Cross.
A153 Targeting immune therapy for childhood ependymoma. Andrea M Griesinger, Rebecca J
Josephson, Andrew M Donson, Jean M Mulcahy Levy, Vladimir Amani, Diane K Birks, Lindsey M Hoffman,
Steffanie L Furtek, Philip Reigan, Michael H Handler, Rajeev Vibhakar, Nicholas K Foreman.
A154 Downregulation of Spin90 in stromal fibroblasts promotes cancer metastasis by remodeling
tumor microenvironment. Yun Hyun Huh, Ah-reum Kwon, Je-Hwang Ryu, Woo Keun Song.
A155 Unmasking cancer to innate sensing by anti-CD47 antibody triggers adaptive immunemediated destruction of immunogenic tumors. Meng Xu.
Other
A156 Anti-p53 auto-antibody serum profiling using high-density peptide arrays. Ken C Lo, John C.
Tan, Eric Sullivan, Ryan Bannen, Todd Richmond, Florian Grupp, Stefan Weiser, Dieter Heindl, Klaus-Peter
Stengele, Albert Thomas.
A157 Oncolytic poliovirus mediated immune events. Michael C Brown, Eda K Holl, David Boczkowski,
Darell D Bigner, Matthias Gromeier, Smita K Nair.
A158 MAGED4B specific peptides: short or long or combination? Kue Peng Lim, Ai Leng Chun,
Sathibalan Ponniah, Sok Ching Cheong.
A159 Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older
patients: A meta-analysis of randomized controlled trials. Tomohiro Funakoshi, Hyman Muss, Stergios
Moschos.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A160 Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming
these cells for enhanced ROS production and tumor cell cytotoxicity. Steven M Leonardo, Ross B
Fulton, Lindsay R Wurst, Keith B Gorden, Adria Bykowski Jonas, Xiaohong Qui, Anissa SH Chan, Jeremy R
Graff.
A161 Angiotensin II type 1 receptor antagonism suppresses tumor metastasis through inhibition of
CCL2-CCR2 mediated monocyte recruitment. Daniel P Regan, Amanda M Guth, Ryan J Hansen, Daniel L
Gustafson, Steven W Dow.
A162 Cancer-specific T cell receptor isolation for cancer immunotherapy. Ruth Ryan, Linda Hibbert,
Luise Weigand, Samantha Paston, Debbie Baker, Zoe Donnellan, Vanessa Clark, Kathy Hale, Louise Conlon,
Joseph Dukes, Caroline Boudousquie, Giovanna Bossi, Emma Hickman, Alex Powlesland, Annelise Vuidepot,
Namir Hassan, Bent Jakobsen.
A163 Tertiary lymphoid structures: Prognostic significance and relationship with tumor-infiltrating
lymphocytes in triple-negative breast cancer. In Ah Park, Hee Jin Lee, In Hye Song, Joo Young Kim, Jong
Han Yu, Gyungyub Gong.
A164 Genetically modified cytokine-induced killer (CIK) cells for targeted cancer therapy. Sarah
Oelsner, Juliane Wagner, Miriam E Friede, Verena Pfirrmann, Eva Rettinger, Ralf Schubert, Heike Pfeifer,
Evelyn Ullrich, Peter Bader, Winfried S Wels.
A165 Engineering approaches to uncover the mechanism of apoptotic cell clearance by a conserved
signaling system. Adam Williamson, Ron Vale.
A166 Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune
system. Yang Eric Guo, Richard Young.
A167 Functional analysis of DNA sensors in the interferon stimulatory DNA (ISD) Pathway. Elizabeth
Gray, Daniel Stetson.
A168 Towards an understanding of the structural basis of CXCR7 ligand binding and signaling.
Martin Gustavsson, Yi Zheng, Ling Qin, Lauren G Holden, Irina Kufareva, Tracy M Handel.
A169 NY-ESO-1 protein cancer vaccine with TLR 3 and 4 agonists. Tomohira Takeoka, Hirotsugu
Nagase, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Tomoki Makino, Makoto Yamasaki, Shuji
Takiguchi, Masaki Mori, Yuichiro Doki, Hisashi Wada.
A170 The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines. Melanie
Mueller, Ralf Amann, Thomas Feger, Hans-Georg Rammensee.
A171 Long-term episomal gene transfer for safe engineering of T-cells for adoptive cell therapy of
cancer. Chuan Jin, Mohanraj Ramachandran, Grammatiki Fotaki, Berith Nilsson, Magnus Essand, Di Yu.
A172 Allogeneic dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as
adjuvant for cancer immunotherapy. Grammatiki Fotaki, Chuan Jin, Alex Karlsson-Parra, Di Yu, Magnus
Essand.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A173 Inhibition of the STING pathway by the AIM2 inflammasome. Leticia Corrales, Seng-Ryong Woo,
Thomas F Gajewski.
A174 Mechanistic Elucidation of Activation-induced Deaminase (AID) in Immunity and Cancer. Qi
Qiao, Li Wang, Feilong Meng, Hao Wu.
A175 Design and evaluation of novel natural killer cell chimeric antigen receptors. David L
Hermanson, Branden Moriarity, Trevor Argall, Melissa A Geller, David Largaespada, Dan S Kaufman.
A176 Efficacy and safety of allogeneic double negative T cell as anti-AML therapy and its underlying
mechanism. Jong Bok Lee, Claire Weihsu Chen, Mark D Minden, John E Dick, Li Zhang.
A177 2’-5’ oligoadenylates mediate innate immune crosstalk between antiviral RNA and DNA
sensors. Jonathan M Clingan, Sterling C Eckard, Daphne A Cooper, Hilario J Ramos, Jaime Guillen, Bruno
Canard, Michael Gale, Jay R Hesselberth, David J Barton, Joshua J Woodward, Daniel B Stetson.
A178 Oncolytic rhabdovirus and inhibitor of apoptosis (IAP) protein antagonist for cancer therapy.
Dae-Sun Kim, Himika Dastidar, Keith Lau, Chunfen Zhang, Douglas J Mahoney.
A179 Ex-vivo generation of clinical grade T cells by using activating and propagating feeder cells to
cross-link T cell receptor. Bipulendu Jena, Hiroaki Taguchi, Aleksandra Nowicka, Ana B Korngold, Helen
Huls, Laurence JN Cooper.
A180 Topologically associated domains genome-wide restrict the off-target activity of
recombination activating gene 1/2 endonuclease. Jiazhi Hu, Yu Zhang, Lijuan Zhao, Richard Frock, Zhou
Du, Robin M Meyers, Feilong Meng, David G Schatz, Frederick W Alt.
A181 Dissecting the spatiotemporal functions of WAVE complex during chemotaxis using CRISPR
and optogenetics. Brian R Graziano, Orion D Weiner.
A182 Zbtb7b is involved in the association of EBF1 enhancer to the nuclear lamina during early B cell
commitment. Yina Zhu, Cornelis Murre.
A183 Molecular elucidation of the CBM complex in NF-kappaB activation by using single molecule
imaging and structural studies. Liron David, Hao Wu.
A184 Listeria-32P, a new approach to treat pancreatic cancer. Dinesh Chandra, Ziqiang Yuan, Steven K
Libutti, Ekaterina Dadachova, Claudia Gravekamp.
A185 Hypercholesterolemia impairs immunosurveillance against colorectal cancer by inhibiting Tet1
dependent differentiation of HSCs towards NKT and gammadelta T cells. Guodong Tie, Jinglian Yan,
Julia Messina, April Deng, Sarah Hainer, Joonsoo Kang, Thomas Fazzio, Louis Messina.
A186 Development of novel lipid based adjuvants and bacterial vector systems for cancer
immunotherapy. Lakshmi Krishnan, Rahul Kushwah.
A187
Genome-wide screening of programmed cell death pathways. Will Bailis, Ruaidhri Jackson.
CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival
September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY
Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m.
A188 The effects of cellular context on miR-155 mediated regulation of gene expression. Jing-Ping
Hsin, Yuheng Lu, Gabriel B. Loeb, Christina S. Leslie, Alexander Y. Rudensky.
A189 Direct antimicrobial and cytotoxic activity of mucosal activated invariant T cells. Yvonne K
Mburu, Flavia Castellano, Valérie Moliner-Frenkel, Olivier Lantz.
A190 VSV-GP in single and combination therapy is a potent oncolytic virus platform for the
treatment of melanoma. Zoltan Banki, Iris Koske, Reinhard Tober, Carles Rodriguez Urbiola, Isabel
Barnstorf, Alexander Muik, Lisa Egerer, Janine Kimpel, Dorothee von Laer, Guido Wollmann.
A191 Augmenting the therapeutic efficacy of oncolytic LCMV-GP pseudotyped Vesicular Stomatitis
Virus via modulation of the innate immune system. Carles Rodriguez Urbiola, Catherine Dold, Janine
Kimpel, Christian Marth, Frederic Santer, Zoran Culig, Alexander Muik, Tanja Knapp, Ira Winkler, Guido
Wollmann, Dorothee Von Laer, Patrik Erlmann.
A192 Oscillatory genes involved in lymphocyte retention and egress. Hsin Chen, Timothy Schmidt,
Ying Xu, Jason G Cyster.
A193 Bioengineered Dectin-1 CAR+ T cells to control invasive fungal infection. Pappanaicken R
Kumaresan, Nathaniel Albert, Harjeet Singh, Simon Olivares, Sourindra N Maiti, Tiejuan Mi, Helen Huls,
Richard E Champlin, Dimitrios P. Kontoyiannis, Laurence J.N. Cooper.
A194 Delta-24-RGDOX: expressing OX40L in gliomas using replication competent oncolytic
adenoviruses induces anti-tumor effect and anti-glioma immune memory. Hong Jiang, Candelaria
Gomez-Manzano, Karen Clise-Dwyer, Laura Bover, Luis M Vence, Frederick F Lang, Charles A Conrad, Carlo
Toniatti, Frank Tufaro, Juan Fueyo.
Clinical Trials of Cancer Immunotherapies
A195 Tremelimimab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma.
Firouzeh Korangy, Mei ElGindi, Drew Pratt, David Venzon, Austin Duffy, Oxana Makarova-Rusher, Sid Kerkar,
David Kleiner, Bradford Wood, Tim Greten.